Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy

This article was originally published in PharmAsia News

Executive Summary

Takeda is discontinuing development of a Phase II compound, TAK-128, for the treatment of peripheral diabetic neuropathy after the candidate failed to show sufficient efficacy to support its continued development, the company reported

You may also be interested in...



Takeda Drops Phase II Diabetes Drug

Compound fails to measure up to exisiting treatments, firm says.

Takeda/BioNumerik’s Tavocept Phase III Data Did Not Meet Primary Endpoints

Takeda will consider terminating its licensing and development agreement for the investigational drug.

Takeda’s Combo Duetact Will Launch Later This Year For Type 2 Diabetes

Takeda's existing Actos sales force will detail the pioglitazone and glimepiride combination therapy to primary care physicians.

Topics

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel